LRA Salutes RemeGen on FDA Fast-Track Designation for Potential Lupus Treatment
April 16, 2020 The Lupus Research Alliance is pleased to share news that promises to speed up testing and review of a potential new treatment for lupus. The U.S. Food and Drug Administration granted fast-track designation to RC18, in development by a company in China, RemeGen. The FDA defines fast track as “a process designed […] Read More